Replies to post #588751 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

MOS literally went down after the control patients were removed.

False. Again. The original control were allowed to cross over per the mandate by the FDA. This was done for ethical reasons. Most patients crossed over. That left, according to Dr. Liau's Musella presentation, only 29 control patients. Dr. Liau stated that most of this 29 died early or were lost to follow up. She went on to state that it would be inappropriate to use this data as a control arm because it only contained 29 patients. She never disclosed the numbers for the 29 patients. Of the patients that were in the original control arm that were allowed to crossover, this became the rGBM arm. The current standard of care for rGBM is palliative. The OS is 7.8 months. The rGBM data for DCVax-L was astonishing. See figure 3 below.

[SkyLimit2022]

iclight,

Thanks for reposting your opinions again, but you need better sources of information. Regarding the ECA/crossover design and the SAP, please review the video recording of Dr. Ashkan at ASCO 2022 and the JAMA Oncology podcast recording of Dr. Liau. Both recordings are included at the links below.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171254048

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171254756

Always verify what you find posted online. Do your own research. Seek trustworthy full-context sources.